Each May in the U.S. is National Osteoporosis Awareness and Prevention Month which is observed to raise awareness about osteoporosis as well as promote prevention and early detection. Bone health is one of the cornerstones of endocrine science and practice, so we felt that this was the perfect issue to highlight some of the recent research focusing on bone health and potential treatment breakthroughs from bone-specific sessions at ENDO 2026 taking place next month in Chicago, Ill.
In “Unpausing the Conversation: Menopause Is Having a Moment at ENDO 2026,” Kelly Horvath takes a closer look at women’s bone health as it takes center stage in Chicago during the symposium “Hot and Flashy: Topics in Menopause,” on Saturday June 13. From catching endocrinologists up regarding menopause care and past regulatory missteps to estrogen’s impact on bone health and the many non-hormonal options, this ENDO 2026 symposium will definitely give attendees something to talk about! The session chair, Gina Woods, MD, MSCP, clinical professor of medicine and chief of the Division of Endocrinology and Metabolism at the University of California, San Diego, thinks that the reason this topic is now being featured is due to the “reevaluation of safety and the U.S. Food and Drug Administration’s removal of the black box warning for menopausal hormone therapy, the ongoing social media buzz, the increased patient demand,” she says. “I think another important component is that the Endocrine Society recognizes that menopause training has been largely missing from medical education. There is a huge knowledge gap, and we need to address it by bringing experts together in sessions like this.”
In “Boning Up: The Year in Bone Health,” Senior Editor Derek Bagley looks at the ENDO 2026 session, “The Year in Bone,” which will feature experts in bone research who will review and discuss the most influential and cutting‑edge publications from the past year. From basic science discoveries, translational advances, and key updates in clinical research, attendees will get a comprehensive overview of the latest progress shaping the field of bone health and disease, which is becoming more and more relevant as the years go by. “We are now living in a super-aged society, and conditions such as osteoporosis and sarcopenia are becoming increasingly important,” says Yumie Rhee, MD, PhD, professor, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, and one of the sessions presenters. “In this setting, I hope attendees will come away with a clear and up-to-date overview of where the field currently stands, as well as the direction in which it is moving through the efforts of many scientists and the pharmaceutical industry.”
“Breaking Point: Weight Loss Therapies and the Musculoskeletal Stakes” by Kelly highlights the ENDO 2026 session, “Weight Loss: Friend or Foe for Bone & Muscle?” Attendees to this symposium will be in for a treat as three experts weigh in on the impact of various weight loss therapies on muscle and bone. Pharmacologic, surgical, and even lifestyle impacts will be discussed and debated in this Sunday morning symposium. One of the session’s speakers will be 40-year Endocrine Society member Clifford J. Rosen, MD, director and principal investigator, Rosen Musculoskeletal Laboratory Clinical & Translational Medicine, Maine Medical Center Research Institute; professor of medicine, Tufts University School of Medicine, Scarborough, Maine, who says we don’t understand the mechanisms of bone loss from the GLP-1 RAs but weight loss alone causes bone to change and thin,” he says, adding, “There might be other mechanisms as well for GLP-1 RAs.”
Next month, we take a broader look at what attendees can expect from ENDO 2026 in Chicago, so be sure to keep an eye out for the June issue! If you have any suggestions, questions, or comments, feel free to contact me at: [email protected].
Loading ...